| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10158392 | Clinical Therapeutics | 2018 | 19 Pages |
Abstract
Coadministration of ritonavir with BZF961 boosted BZF961 exposure (including Cmin, which is the clinically relevant parameter associated with antiviral activity) in a therapeutic range with less variability compared with BZF961 alone. For strategic reasons, BZF961 is no longer under development.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Eric MD, Mohamed MD, Thomas MD, Christopher T. PhD, Avantika PhD, Baldur PhD, David T. PhD, Ursula PhD, Kathryn PhD, Erica MS, Darlene MS, Kristina PharmD, Tycho PhD, Marjorie MS, Catherine L. PhD, Steven J. PharmD, Jay P. PhD, Bin PhD, Richard A. MD,